Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 11Sarcoma 4Carcinoma, Merkel Cell 2Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Paget Disease, Extramammary 1Neoplasm Metastasis 1Mycosis Fungoides 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma 1Leiomyosarcoma 1Inflammatory Breast Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Basosquamous 1Carcinoma, Basal Cell 1Breast Neoplasms 1Adenocarcinoma, Papillary 1

Interventions

Paclitaxel 6Doxorubicin 6Gemcitabine 4Bevacizumab 4pembrolizumab 3pazopanib 3durvalumab 3Sorafenib 3Docetaxel 3trebananib 2spartalizumab 2cemiplimab 2brostallicin 2Propranolol 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Imatinib Mesylate 2Ifosfamide 2Carboplatin 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trastuzumab duocarmazine 1temsirolimus 1talimogene laherparepvec 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemangiosarcoma × talimogene laherparepvec × Clear all
NCT03921073 2022-11-01

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 5 charts
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡